NSEI:ADVENZYMES

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Advanced Enzyme Technologies

Market Cap

₹44.7b

Last Updated

2021/07/23 12:07 UTC

Data Sources

Company Financials +

Executive Summary

Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. More Details

Rewards

Earnings are forecast to grow 18.58% per year

Earnings have grown 12.6% per year over the past 5 years

Risk Analysis

No risks detected for ADVENZYMES from our risk checks.


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has Advanced Enzyme Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADVENZYMES is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ADVENZYMES's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-3.5%

ADVENZYMES

1.4%

IN Chemicals

-0.1%

IN Market


1 Year Return

146.3%

ADVENZYMES

81.4%

IN Chemicals

53.0%

IN Market

Return vs Industry: ADVENZYMES exceeded the Indian Chemicals industry which returned 81.4% over the past year.

Return vs Market: ADVENZYMES exceeded the Indian Market which returned 53% over the past year.


Shareholder returns

ADVENZYMESIndustryMarket
7 Day-3.5%1.4%-0.1%
30 Day-3.0%5.8%1.3%
90 Day3.8%25.9%14.9%
1 Year146.3%146.3%83.2%81.4%55.1%53.0%
3 Year93.9%92.0%116.5%106.1%40.2%33.0%
5 Yearn/a195.8%176.3%82.5%67.3%

Long-Term Price Volatility Vs. Market

How volatile is Advanced Enzyme Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Advanced Enzyme Technologies undervalued compared to its fair value and its price relative to the market?

30.53x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ADVENZYMES (₹399.65) is trading above our estimate of fair value (₹292.9)

Significantly Below Fair Value: ADVENZYMES is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ADVENZYMES is poor value based on its PE Ratio (30.5x) compared to the Indian Chemicals industry average (20.1x).

PE vs Market: ADVENZYMES is poor value based on its PE Ratio (30.5x) compared to the Indian market (23.8x).


Price to Earnings Growth Ratio

PEG Ratio: ADVENZYMES is poor value based on its PEG Ratio (1.6x)


Price to Book Ratio

PB vs Industry: ADVENZYMES is overvalued based on its PB Ratio (4.6x) compared to the IN Chemicals industry average (2.2x).


Future Growth

How is Advanced Enzyme Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

18.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADVENZYMES's forecast earnings growth (18.6% per year) is above the savings rate (6.8%).

Earnings vs Market: ADVENZYMES's earnings (18.6% per year) are forecast to grow slower than the Indian market (21.2% per year).

High Growth Earnings: ADVENZYMES's earnings are forecast to grow, but not significantly.

Revenue vs Market: ADVENZYMES's revenue (11.2% per year) is forecast to grow slower than the Indian market (12.6% per year).

High Growth Revenue: ADVENZYMES's revenue (11.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ADVENZYMES's Return on Equity is forecast to be low in 3 years time (15.7%).


Past Performance

How has Advanced Enzyme Technologies performed over the past 5 years?

12.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADVENZYMES has high quality earnings.

Growing Profit Margin: ADVENZYMES's current net profit margins (28.9%) are higher than last year (28.9%).


Past Earnings Growth Analysis

Earnings Trend: ADVENZYMES's earnings have grown by 12.6% per year over the past 5 years.

Accelerating Growth: ADVENZYMES's earnings growth over the past year (13.1%) exceeds its 5-year average (12.6% per year).

Earnings vs Industry: ADVENZYMES earnings growth over the past year (13.1%) underperformed the Chemicals industry 27%.


Return on Equity

High ROE: ADVENZYMES's Return on Equity (14.7%) is considered low.


Financial Health

How is Advanced Enzyme Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: ADVENZYMES's short term assets (₹5.2B) exceed its short term liabilities (₹675.6M).

Long Term Liabilities: ADVENZYMES's short term assets (₹5.2B) exceed its long term liabilities (₹543.5M).


Debt to Equity History and Analysis

Debt Level: ADVENZYMES's debt to equity ratio (0.9%) is considered satisfactory.

Reducing Debt: ADVENZYMES's debt to equity ratio has reduced from 35.4% to 0.9% over the past 5 years.

Debt Coverage: ADVENZYMES's debt is well covered by operating cash flow (1844.5%).

Interest Coverage: ADVENZYMES's interest payments on its debt are well covered by EBIT (130x coverage).


Balance Sheet


Dividend

What is Advanced Enzyme Technologies's current dividend yield, its reliability and sustainability?

0.22%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ADVENZYMES's dividend (0.23%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.36%).

High Dividend: ADVENZYMES's dividend (0.23%) is low compared to the top 25% of dividend payers in the Indian market (1.44%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, ADVENZYMES has been paying a dividend for less than 10 years.

Growing Dividend: ADVENZYMES's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (6.9%), ADVENZYMES's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: ADVENZYMES's dividends in 3 years are forecast to be thoroughly covered by earnings (6.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Advanced Enzyme Technologies has no CEO, or we have no data on them.


Leadership Team

Experienced Management: ADVENZYMES's management team is seasoned and experienced (5.8 years average tenure).


Board Members

Experienced Board: ADVENZYMES's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Advanced Enzyme Technologies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advanced Enzyme Technologies Limited
  • Ticker: ADVENZYMES
  • Exchange: NSEI
  • Founded: 1957
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: ₹44.667b
  • Shares outstanding: 111.78m
  • Website: https://www.advancedenzymes.com

Number of Employees


Location

  • Advanced Enzyme Technologies Limited
  • Sun Magnetica
  • 5th Floor, A wing
  • Thane
  • Maharashtra
  • 400604
  • India

Listings


Biography

Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/23 12:07
End of Day Share Price2021/07/22 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.